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Abstract
Equivalence testing is of emerging importance in genomics studies
but has hitherto been little studied in this content. In this paper,
we define the notion of equivalence of gene expression and determine
a ‘strength of evidence’ measure for gene equivalence. It is common
practice in genome-wide studies to rank genes according to observed
gene-specific P -values or adjusted P -values, which are assumed to
measure the strength of evidence against the null hypothesis of no
differential gene expression. We show here, both empirically and for-
mally, that the equivalence P -value does not satisfy the basic consis-
tency requirements for a valid strength of evidence measure for equiva-
lence. This means that the widely-used q-value (Storey, 2002) defined
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for each gene to be the minimum positive false discovery rate that
would result in the inclusion of the corresponding P -value in the dis-
covery set, cannot be translated to the equivalence testing framework.
However, when represented as a posterior probability, we find that
the q-value does satisfy some basic consistency requirements needed
to be a credible measure of evidence for equivalence. We propose a
simple estimate for the q-value from posterior probabilities of equiva-
lence, and analyse data from a mouse stem cell microarray experiment
which demonstrate the theory and methods presented here.
Keywords: EM algorithm; equivalence testing; false discovery rate; P -
value; posterior probability; q-value; stem cell microarray experiment.
1 Introduction
1.1 Motivation for equivalence testing in genomics
Equivalence testing is pervasive in the pharmaceutical industry for assessing
whether two drugs or treatment regimens provide comparable therapeutic
effects within pre-defined clinical and statistical limits (Senn, 2001; Chow
and Liu, 2008). Typically, a new treatment formulation is of interest if it
potentially provides an equivalent therapeutic effect with fewer adverse side-
effects than the standard treatment, or is less costly to produce. In such
trials, a fixed level of statistical significance is usually prescribed and within
this context, tests based on confidence interval inclusion provide a sound
basis for analysis (Westlake, 1972; Wellek, 2003).
Recently, a number of important applications entailing hypotheses of
equivalence have arisen in the area of microarray bioinformatics and genomics
studies, as illustrated by the following.
Illustration 1: Gene profiling. There are biological problems in which it is
desired to establish that the levels of expression for certain genes remain
constant across different conditions and/or points in time. Tuke et al. (2009)
propose a general method for ranking genes according to their conformance
to a pre-specified profile of expression over time, known as gene profiling. In
many situations, the expected time-course profile dictates that gene expres-
sion should remain the same, or be equivalent, at two or more different time
points, and hence equivalence testing methods are required as part of the
statistical inferential framework.
Illustration 2: Experimental study of regulatory T cells of the immune sys-
tem. CD4+CD25+ regulatory T cells (known as CD4+ Treg cells) play a
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central role in the human immune system, including in the immunopatho-
genesis of autoimmune diseases, tumours, viral infections such as HIV, and
organ transplants (Wei, 2006). Naturally occurring CD4+ Treg cells are
available only in very small quantities however, and for this reason many in
vitro experiments are conducted on induced cell populations. To ensure the
integrity of such experiments, it is desirable to establish that gene expression
is equivalent between the naturally occurring and induced cells, at least un-
der baseline conditions. The establishment of such conditions requires direct
formal testing of an equivalence hypothesis, rather than simply failing to find
evidence of differential expression between the two populations.
Illustration 3: Normalisation and quality assurance. A third and common
problem for which methods of equivalence testing are appropriate in practice
(although not always applied) is in the identification of highly stable genes or
set of genes for the purpose of quality assurance, or for normalisation for use
in future experiments. The identification of such genes (often housekeeping
genes of some variety) is particularly important in large-scale studies utilising
a reference population and conducted over time, such as in cancer studies.
The reference population may be subject to temporal or other changes, and
linkage experiments are usually conducted to ensure comparability of results
and diagnoses over time.
In each of these illustrations, the aim of the scientific experiment is to
test one or more hypotheses of equivalence. In a typical experiment, many
thousands of genes will be tested simultaneously, and a primary goal of an
initial bioinformatics exploratory analysis, known as a ‘gene-screen’, is to
produce a ranked gene list. Therefore, we require an inferential strength of
evidence measure for equivalence which will give just such a ranking.
Now, we know that there are two types of mistakes we can make when
testing a statistical hypothesis: the first is Type I error, which is the proba-
bility of rejecting the null hypothesis when it is true, and the second is Type
II error, which is the probability of retaining the null hypothesis when it is
false. Type I errors are also known as false positives, and it is their dramat-
ically increased frequency in genomics applications which has received most
attention. A popular approach to adjusting for multiple hypotheses testing
in this context is to find the observed P -value for each gene, and then to
calculate its associated q-value (Storey, 2003). For each gene, the observed
q-value is the positive false discovery rate (pFDR) that would result in the
corresponding P -value being included in the discovery set, should this be the
adjustment procedure applied. The pFDR itself is the rate at which genes
are incorrectly discovered to be significant; there are also other methods for
controlling the Type I error at a reasonable level, for example, controlling the
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overall family-wise error rate, but the pFDR is popularly applied in genomics
studies.
In Section 2, we review the formal definition of the q-value, then derive
the equivalence P -value for each gene. We show that our P -value equates
to alternative derivations by Senn (2001) and Ge et al. (2003). We then
point out problems with equivalence P -values, in particular, that they tend
to zero as the standard error of the estimator increases, and that they are
non-monotonic, thus rendering them unsuitable as a basis for calculating
equivalence q-values. In Section 3, we describe the q-value as a posterior
probability, and prove that the equivalence q-value obtained in this way
is a monotonic function of the standard error of the estimator of interest,
thus satisfying the basic consistency requirement (among other things) for
a strength of evidence measure for the gene ranking. We also show how to
estimate q-values from the observed posterior probabilities for equivalence.
In Section 4, we set out our motivating analysis of a murine stem cell
microarray experiment conducted at the University of Adelaide. The over-
all aim of the larger time course experiment was to identify and investigate
genes involved in pluripotency. We are interested in which of the 23, 040
mouse genes are equivalently expressed at day 0 (i.e., the beginning of the
experiment) and at day 3. We begin by proposing a joint probability model
for the observed and true log ratios to obtain the posterior probability of
equivalence; we employ an empirical rather than a fully Bayesian approach
to estimation, utilising the EM algorithm to estimate the specified hyperpa-
rameters. We finish with a brief conclusion in Section 5 extolling the virtues
of the q-value, when represented as a posterior probability, as a credible
measure of evidence for equivalence.
2 Equivalence P -values and q-values
2.1 The positive false discovery rate and the q-value
We are interested in the positive false discovery rate (pFDR) due to Storey
(2003). To review, Table 1 gives the possible outcomes when m hypotheses
tests are performed according to some significance rule:
The positive false discovery rate is then defined as
pFDR = E [V/R|R > 0]
In genomics studies, and for equivalence testing in particular, R > 0
almost always, so we assume from now on that the pFDR is the same as the
FDR.
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Accept null Reject null Total
Null true U V m0
Alternative true T S m1
W R m
Table 1: Possible outcomes from m hypotheses tests.
Now suppose that for each of the m hypotheses, the test statistics
T1, T2, . . . , Tm are observed. Consider a nested set of significance regions
denoted by Γα, 0 ≤ α ≤ 1, where α is such that
P (Ti ∈ Γα|ith null hypothesis is true) = α
and α′ ≤ α implies that Γα′ ⊂ Γα. Storey (2003) defines the q-value for an
observed test statistic T = t to be
q-value(t) = inf
Γα:t∈Γα
pFDR(Γα) (1)
We return to the general definition (1) in Section 3.
2.2 P -values for equivalence testing
Consider a parameter of interest θ and its associated estimator, θˆ, such that
θˆ ∼ N(θ, SE(θˆ)2),
i.e., θˆ is an unbiased estimator of θ. For simplicity, but without loss of
generality, we assume that the standard error of the estimator θˆ is known.
In statistical equivalence testing, the null and alternative hypotheses are,
respectively,
H0 : |θ| ≥ ε, ε > 0, (2)
HA : |θ| < ε (3)
Consider now the test statistic,
U(θˆ) =
ε− |θˆ|
SE(θˆ)
(4)
The test statistic is chosen so that large values give evidence in favour of
HA. From (4), we can deduce that as the observed value of the estimator
gets closer to zero from either direction, then the test statistic increases to
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a maximum at ε/SE(θˆ), while as the observed value of the estimator moves
away from zero, the test statistic decreases.
The following theorem is from Casella (2002, p.397):
Theorem 1: Let W (X) be a test statistic such that large values of W give
evidence that HA is true. For each sample point x, define
p(x) = sup
θ∈Θ0
Pθ(W (X) ≥ W (x)),
where Θ0 is a subset of the parameter space defined by the null hypothesis.
Then, p(X) is a valid P -value.
Applying Theorem 1 to the test statistic (4) yields the P -value
PU = sup
θ∈Θ0
Pθ(U(θˆ) ≥ u(θˆ))
= sup
|θ|≥ε
Pθ
(
−|θˆ| − θ
SE(θˆ)
≤ Z ≤ |θˆ| − θ
SE(θˆ)
)
, (5)
where θˆ is the observed estimate and Z ∼ N(0, 1). It can be shown that PU
is maximised at θ = ±ε, so that
PU = P
(
−|θˆ| − ε
SE(θˆ)
≤ Z ≤ |θˆ| − ε
SE(θˆ)
)
(6)
An alternative derivation of PU uses a Neyman-Pearson-type test, as pro-
posed by Senn (2001). He considers the statistical problem of equivalence
testing for a parameter of interest θ, with an estimator θˆ, such that
θˆ ∼ N(θ, SE(θˆ)2)
Then for a pair of symmetric critical values for θˆ, −c and c, the power function
for a test based on θˆ is
Φ
(
c− ε
SE(θˆ)
)
− Φ
(
−c− ε
SE(θˆ)
)
(7)
To achieve a test of significance level α, equation (7) is set equal to α and
solved for c.
In other work, Ge et al. (2003) state that the P -value is the minimum
Type 1 error over all possible rejection regions that contain the observed
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value of the test statistic. Again consider the observed estimate θˆ. The P -
value associated with this observed estimate, which is denoted by Palt can
therefore be derived from the power function (7):
Palt = min
c:θˆ∈(−c,c)
Φ
(
c− ε
SE(θˆ)
)
− Φ
(
−c− ε
SE(θˆ)
)
= Φ
(
|θˆ| − ε
SE(θˆ)
)
− Φ
(
−|θˆ| − ε
SE(θˆ)
)
= PU
which again recovers our estimate (6).
2.3 Inconsistency of equivalence P -values
The P -value is often interpreted as a strength of evidence measure for the
alternative hypothesis. For example, Casella and Berger (2002) state that
small values of the P -value give evidence that the alternative hypothesis is
true (Definition 8.3.26, page 397). This is not true, however, for equivalence
P -values, as we now demonstrate.
Consider Equation (6) as a function of SE(θˆ), with θˆ and ε fixed. In
general, as SE(θˆ) increases, then PU decreases to zero. This is illustrated
in Figure 1 which plots PU versus SE(θˆ) for values of θˆ of 0.5, 1, and 2,
and ε = 1. For each value of θˆ, as SE(θˆ) increases, then PU decreases to
zero. Thus, small values of PU do not necessarily indicate evidence that
the alternative hypothesis is true, i.e., that θ is equivalent to zero. For
example, consider an observed value of θˆ = 0.5, with SE(θˆ) = 10. For these
observed values, we are 95% confident that the true value of θ lies between
−19.09964 and 20.09964, but the observed value of PU for the equivalence
margin of (−1, 1) is 0.03969. This small value of PU indicates strong evidence
that θ lies between −1 and 1, which is false. In fact, the largest confidence
interval that would be wholly contained within the equivalence margin is a
52% confidence interval.
A further observation of note is the lack of monotonicity of PU as SE(θˆ)
increases. This is illustrated by the graph of PU versus SE(θˆ) for the case
θˆ = 0.5 in Figure 1. As SE(θˆ) increases from 0 to 1, PU increases to a
maximum of about 0.24, then PU decreases as SE(θˆ) increases from 1 to 20.
As a result of this lack of monotonicity, it is possible to have the same value
of PU for different values of SE(θˆ). For example, the PU for an observed
value of θˆ = 0.5, an equivalence margin of ε equal to 1, and SE(θˆ) = 0.3, is
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0.04779. This is the same P -value that is observed for the same conditions
but with SE(θˆ) equal to 8.28224. To assign the same strength of evidence
to both of these cases is incorrect.
SE(θ^)
P U
0.0
0.2
0.4
0.6
0.8
1.0
0 5 10 15 20
θ^
0.5
1
2
Figure 1: Equivalence P -value versus SE(θˆ) for an equivalence margin of
ε = 1.
These inconsistencies in interpretation of the observed equivalence P -
values highlight the fact that they lack the basic consistency requirements
necessary to provide a valid strength of evidence measure for equivalence,
either on their own as raw (unadjusted) P -values, or as a basis for (adjusted)
statistics such as the q-value.
We turn instead to a Bayesian formulation, and in particular, propose
the posterior probability of equivalence, as an alternative strength of evidence
measure for equivalence. We justify this approach in the next section and also
show how to calculate approximate q-values from the posterior probabilities.
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3 Monotonicity of posterior probabilities for
equivalence and q-values
In Section 2.1, we defined the q-value, q(t), for m identical hypothesis tests
with corresponding test statistics T1, . . . , Tm and significance region Γ (Storey,
2003).
For each hypothesis test, there is also a corresponding Bernoulli random
variable Hi with Hi = 0 if the null hypothesis is true and Hi = 1 if the
null hypothesis is false. Storey (2003) assumes that (Ti, Hi) are independent
identically distributed random variables, Ti|Hi ∼ (1−Hi)F0 +HiF1 for some
null distribution F0 and alternative distribution F1, and Hi ∼Bernoulli(pi)
for i = 1, . . . ,m, where pi is the a priori probability that a null hypothesis
is false, i.e., P (Hi = 1) = pi. Therefore, the q-value is the infimum of the
quantity P (H = 0|T ∈ Γα), that is, the posterior probability that the null
hypothesis is true given that the test statistic is contained in the significance
region of level α.
The following theorem states that for equivalence testing, the q-value
is monotonically decreasing for increasing variance of the test statistic. We
state the theorem here and defer its proof to Appendix 2, which also contains
the statement and proof of a lemma which is used in the proof of Theorem
2.
Theorem 2: Suppose θ has prior distribution P (θ) and T |θ ∼ N(θ, σ2).
Consider numbers 0 < ` < ε and assume further that 0 < P (−ε < θ < ε) <
1. Then P (−ε < θ < ε | −` < T < `) is a decreasing function of σ2.
Note that for given SE(θˆ), the q-value is intended to estimate the poste-
rior probability
1− P (−ε < θ < ε | −` < T < `),
which we have therefore established increases monotonically with SE(θˆ).
3.1 Estimating q-values from posterior probabilities of
equivalence
Before illustrating the methods on the stem cell microarray data, we take
the development a step further and show how to estimate q-values from the
observed posterior probabilities of equivalence in any given application.
Consider an arbitrary cutoff point t such that all genes will be considered
equivalent if their observed posterior probability of equivalence is greater
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than or equal to t. The FDR for the cutoff t is then
FDR(t) = E
[
V (t)
R(t)
]
,
where R(t) is the number of genes considered equivalent with assumed cutoff
t, and V (t) is the number of genes considered equivalent with cutoff t that are
not in fact equivalent, i.e., these are false positives. Storey (2003) recovers
the general result that
E
[
V (t)
R(t)
]
≈ E[V (t)]
E[R(t)]
In the case of gene equivalence studies, E[R(t)] can be estimated by the
number of genes whose posterior probability of equivalence is greater than or
equal to t. The estimate of E[V (t)] is obtained by considering each hypothesis
test as a Bernoulli random variable Xi, i = 1, . . . ,m, where Xi = 1 if the null
hypothesis is true, that is, |θi| ≥ ε, and Xi = 0 if the null hypothesis is false.
Therefore,
E[V (t)] = E
[∑
i:pi≥t
Xi
]
=
∑
i:pi≥t
E[Xi] =
∑
i:pi≥t
qi,
where
qi = P (|θi| ≥ ε),
and pi is the posterior probability of equivalence for the i
th gene.
The value of qi is unknown but can be estimated from the posterior distri-
bution of θi by qi ≈ 1−pi, where pi is the posterior probability of equivalence
of the ith gene. The estimated q-value for a cutoff point t is then
qˆ(t) =
∑
i:pi≥t(1− pi)
#{i : pi ≥ t} , (8)
where #A represents the cardinality of the set A.
In the next section we explore the performance of the posterior probabil-
ities of equivalence for the stem cell data. We also estimate the approximate
q-values obtained from the posterior probabilities of gene expression equiva-
lence.
4 Gene equivalence in mouse stem cells on
day 0 and day 3
Much of our work on gene equivalence has been motivated by a stem cell
microarray experiment conducted at the University of Adelaide. The overall
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aim of the experiment was to identify and investigate genes involved in the
cellular process of pluripotency; the details of this study and its design are
described in Tuke et al. (2009) and Tuke (2012). Here we are interested in
which of 23, 040 mouse genes are equivalently expressed at day 0 (i.e., the
beginning of the experiment) and at day 3. This equivalence gene-set will
include genes which are not expressed on either day and genes which are
expressed on both day 0 and day 3. We know a priori that there are house-
keeping genes included on the microarray which are highly and constantly
expressed across hybridisations, and that there are genes involved in pluripo-
tency which are also expressed on both days. There are two (dye-swapped)
two-colour mouse Compugen long-oligonucleotide microarrays available for
analysis, which are treated as independent replicates.
We proceed as follows: to begin, we specify a joint distribution for the
true mean log ratio and the observed mean log ratio for each gene, in which
the prior distribution for the true mean log ratio is a mixture model of three
normal distributions. The hyperparameters for the joint distribution are
then estimated from the observed mean log ratios using the EM algorithm
(as described in Appendix 1) and finally the posterior distribution of the true
gene log ratio is derived and used to calculate the posterior probability of
equivalence. We do not use a fully Bayesian formulation for our case study,
but rather estimate the hyperparameters then treat them as ‘known’, thereby
utilising a simpler empirical Bayesian approach.
4.1 The probability model for each gene
The parameter of interest is the true mean log ratio which will be equal to
zero if the gene is equivalently expressed on day 3 and day 0.
If the true mean log ratio for gene i is denoted by θi, i = 1, ..., 23040, then
the sample mean of the observed log ratio, Yi, is assumed to be normally
distributed with mean θi and variance σ
2
i , which is assumed known. The
probability density function for Yi is then
f(yi|θi) = 1√
2piσ2i
exp
[
−(yi − θi)
2
2σ2i
]
The prior probability distribution for θi is assumed to be a mixture model
of three normal distributions. This choice of prior gives flexibility to the
full probability model and is motivated by the data. Figure 2 presents a
histogram of the observed mean log ratios for day 3 compared to day 0
for the data yi, and shows a symmetric bell-shaped density with relatively
heavy tails compared to a normal density. This suggests a t-distribution with
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a small number of degrees of freedom would be an appropriate prior, among
other possibilities, and it is straightforward to show that such a t-distribution
is well approximated by a mixture of three normal distributions.
Observed log ratio
D
en
si
ty
0.0
0.5
1.0
1.5
2.0
2.5
−2 −1 0 1 2 3
Figure 2: Histogram of observed mean log ratios for day 3 compared to day
0 for the mouse stem cell data.
The prior distribution for θi, i = 1, . . . , 23040 is therefore
f(θi) =
3∑
j=1
pij√
2piτ 2j
exp
[
−(θi − µj)
2
2τ 2j
]
with hyperparameters pij, µj, τ
2
j , j = 1, 2, 3 such that
∑3
j=1 pij = 1.
The full probability model for each gene i is then
f(yi, θi) = f(yi|θi)f(θi)
=
1√
2piσ2i
exp
[
−(yi − θi)
2
2σ2i
] 3∑
j=1
pij√
2piτ 2j
exp
[
−(θi − µj)
2
2τ 2j
]
(9)
Under this model, the posterior density function of the true mean log
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ratio for the ith gene, θi, i = 1, . . . , 23040, is
f(θi|yi) = f(yi|θi)f(θi)
f(yi)
=
1√
2piσ2i
exp
[
− (yi−θi)2
2σ2i
]∑3
j=1
pij√
2piτ2j
exp
[
− (θi−µj)2
2τ2j
]
∑3
j=1
pij√
2pi(σ2i+τ
2
j )
exp
[
− (yi−µj)2
2(σ2i+τ
2
j )
] (10)
Rearranging (10) gives
f(θi|yi) = 1
A
3∑
j=1
BjCj exp
[
E2j
2D2j
]√
2piD2j
1√
2piD2j
exp
[
−(θi − Ej)
2
2D2j
]
, (11)
where
A =
3∑
j=1
pij√
2piρ2j
exp
[
−(yi − µj)
2
2ρ2j
]
,
Bj =
pij√
2piσ2i
√
2piτ 2j
,
Cj = exp
[
−(τ
2
j y
2
i + σ
2
i µ
2
j)
2σ2i τ
2
j
]
,
D2j =
σ2i τ
2
j
τ 2j + σ
2
i
, and
Ej =
yiτ
2
j + µjσ
2
i
τ 2j + σ
2
i
Explicit calculation of the normalising constant is a straightforward adapta-
tion of the standard argument used for a Gaussian mean with a Gaussian
prior; see for example, Gelman (2004).
The posterior density (11) is used to calculate the conditional probability
that θi lies within the equivalence region, conditional on the observed mean
log ratio. That is, P (−ε < θi < ε|yi) is equal to
1
A
3∑
j=1
BjCj exp
(
E2j
2D2j
)√
2piD2j
∫ ε
−ε
1√
2piD2j
exp
[
−(θ − Ej)
2
2D2j
]
dθi (12)
As already noted, this is not a fully Bayesian formulation since we have
not specified distributions for the hyperparameters pij, µj and τ
2
j . Rather, we
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take an empirical Bayes approach to obtain point estimates for each of the
nine hyperparameters, which are then substituted into the posterior distri-
bution of θi to obtain posterior probabilities of equivalence. We employ the
EM algorithm to estimate the hyperparameters, and the details are given in
Appendix 1.
4.2 Application to the stem cell data: day 3 compared
to day 0
We know from Equation (11) that the posterior distribution of θi, i =
1, ..., 23040, is a weighted mixture of the likelihood of θi given the data yi and
the prior distribution of θi, i = 1, ..., 23040. We study first the behaviour of
the posterior probability as a function of the variance σ2i .
Observe that if the variance of the mean log ratio σ2i is zero, then yi is
equal to θi and the gene is equivalently expressed if |yi| <  = 1 and not
equivalently expressed if |yi| ≥ 1. This is illustrated in Figure 3 which plots
the posterior probability of equivalence versus the variance of the mean log
ratio, σ2i , for mean log ratios over a range of given values. The estimates
of the hyperparameters used for the calculations implicit in this Figure are
given in Table 4 of Appendix 1.
For mean log ratios contained within (−1, 1) the posterior probability of
equivalence for a value of σ2i = 0 is one, while those that lie outside (−1, 1)
have a posterior probability of equivalence of zero when σ2i is zero. As the
variance of the mean log ratios increases, the posterior distribution of θi,
i = 1, . . . , 23040, is weighted towards the prior distribution of θi. This is
demonstrated by the posterior probability of equivalence increasing to one
for all values of the mean log ratio as the value of σ2i increases to 2.5 in
Figure 3. Of note is that the posterior probability of equivalence is higher
for the (positive) mean log ratios 1.5, 2.5 and 3.5 compared to the negative
means −1.5,−2.5 and −3.5, for the same value of σ2i . This is because the
empirical prior distribution of θi, i = 1, . . . , 23040, is asymmetric about zero.
A scatter plot of the estimated posterior probability of equivalence versus
the observed mean log ratio is shown in Figure 4 with the genes separated by
spot type. The values of the hyperparameters used to calculate the posterior
probabilities are given in Table 4 of Appendix 1, and are the same as the
values used for Figure 3.
We note firstly that there are 327 housekeeping genes spotted on the
microarray, the most common nucleotide being NM 008084 for which there
are 232 spots. This nucleotide is a fragment of the gene glyceraldehyde-3-
phosphate dehydrogenase (Gapdh) which has been validated as a good house-
14
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Figure 3: Posterior probability of equivalence versus variance of the mean
log ratio, σ2i , for the given mean log ratio value.
keeping gene in the mouse embryo (Mamo et al., 2007; Willems et al., 2006).
Housekeeping genes are highly and constantly expressed across hybridisa-
tions, and are useful for quality assurance purposes, among other things. Of
the total 327 housekeeping spots, 316 (96.64%) have a posterior probability
of equivalence greater than 0.9999, whilst all 232 of the NM 008084 spots
have posterior probability of equivalence greater than 0.9999925.
The buffer and control genes are expected to have zero gene expression on
both days, and are also equivalently expressed with high posterior probability,
as expected.
Next, we observe some genes with observed mean log ratios lying outside
the equivalence neighbourhood (−1, 1), but with posterior probabilities of
equivalence close to one. There are 231 genes in total with observed mean
log ratios lying outside of the equivalence neighbourhood, with corresponding
posterior probabilities of equivalence lying between 0.01665 and 0.99779. Of
these 231 genes, 22 have a posterior probability of equivalence greater than
0.99 and all also have a mean log ratio variance greater than 0.2228. This
is a large observed variance, as only 2% of all genes on the microarray have
an observed variance greater than 0.2228, and explains the high posterior
probability of equivalence for these genes, as indicated in Figure 3.
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Figure 4: Posterior probability of equivalence versus observed mean log ratio
for the stem cell genes: day 3 compared to day 0.
In Tuke et al. (2009), the authors identified, with gene profiling, 15 nu-
cleotides whose observed expression levels over time correspond to the pre-
specified profile referred to as the Oct4 profile. These nucleotides and associ-
ated gene are shown in Table 2 along with their observed posterior probability
of equivalence. The Oct4 profile requires the nucleotides to have equivalent
expression at day 3 compared to day 0 and so we expected that these nu-
cleotides would have a posterior probability of equivalence close to one as
seen in the table.
Figure 5 plots the estimated q-values (8) versus the posterior probabilities
of equivalence for the stem cell mean log ratios comparing day 3 to day 0,
and shows good concordance. We observe that as the posterior probability
of equivalence decreases, the q-value increases to a maximum of 0.003069.
This small observed maximum q-value is because the majority of genes are
expected to be equivalently expressed between day 3 and day 0 and so even
if all genes are considered equivalent then the expected proportion of false
positives will be small.
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Nucleotide Posterior Probability
NM 013633 (Oct4) 0.998
NM 009482 (Utfl) 0.9989
NM 011562 (Tdgf1) 0.9983
AK005182 (Slc35f2) 0.9992
NM 009426 (Trh) 0.9985
NM 010425 (Foxd3) 0.9993
AF246632 (Musd1) 0.9988
BC004805 (Skil) 0.9986
NM 010127 (Pou6f1) 0.9988
NM 007974 (Par2) 0.9974
AK010332 (Nanog) 0.9966
NM 007515 (Slc7a3) 0.9986
NM 010316 (Gng3) 0.9994
NM 011386 (Skil) 0.9986
NM 007905 (Rae-28) 0.9996
Table 2: Nucleotides identified by gene profiling with the Oct4 profile (Tuke
et al., 2009) and their associated posterior probability of equivalence.
5 Conclusion
We have shown in a general setting that the q-value, when represented as a
posterior probability, satisfies some basic consistency requirements needed for
any credible measure of evidence for equivalence. In particular, the q-value
increases monotonically with the variance of the estimator. Importantly,
we have established that the P -value does not satisfy these requirements,
and hence should not be used as a measure of evidence for equivalence.
Our results also demonstrate that any attempt to adapt Storey’s approach
to estimating q-values from P -values in the equivalence testing context is
logically untenable, and propose a simple alternative estimate. We note
that the lack of duality between P -values and q-values in equivalence testing
provides some fuel to the debate on the P -value as a measure of evidence per
se, but discussion on this point is beyond the scope of the present paper.
It is worth remarking here that via simulations conducted (but not shown),
the empirical Bayesian model we assumed of a mixture of three normal dis-
tributions provides a reasonable approximation to the true posterior prob-
ability of equivalence, even in situations where the true prior distribution
of the parameter of interest deviates considerably from a mixture model of
three normals.
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Figure 5: Estimated q-value versus posterior probability of equivalence for
the stem cell data: day 3 compared to day 0.
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Appendix 1: Estimation of hyperparameters
using the EM algorithm
Applying the EM algorithm to the full probability model (9) for the observed
mean log ratios, Yi, we introduce the Bernoulli random variables Ri1, Ri2 and
Ri3, i = 1, . . . , 23040, that are unobserved in the data.
The complete likelihood for the observed data vector Y and the unob-
served data R1,R2 and R3 is then
L(Ψ|Y ,R1,R2,R3) =
23040∏
i=1
3∏
j=1
[
pijgj(yi, µj, τ
2
j )
]Rij ,
where
gj(yi, µj, τ
2
j ) =
1√
2pi(τ 2j + σ
2
i )
exp
{
− (yi − µj)
2
2(τ 2j + σ
2
i )
}
, j = 1, 2, 3,
∑3
j=1 pij = 1, and Ψ = (pi1, pi2, pi3, µ1, µ2, µ3, τ
2
1 , τ
2
2 , τ
2
3 ).
That is, the log-likelihood is
`(Ψ|Y ,R1,R2,R3) =
23040∑
i=1
3∑
j=1
Rij log pij +Rij log gi(yi, µj, τ
2
j ) (13)
For exponential family distributions, the conditional expectation of the
complete log likelihood Q(Ψ|Ψn), conditional on the estimated value Ψn of
Ψ at the nth step, can be calculated by substituting E[Z|Y ,Ψn] in place
of Z, where Z represents the missing data (Dempster et al., 1977). For the
observed mean log ratio for gene i,
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E[Rij|Y ,Ψn] = P (Rij = 1|Y ,Ψn)
=
pi
(n)
j gj(yi, µ
(n)
j , τ
2(n)
j )∑3
j=1 pi
(n)
j gj(yi, µ
(n)
j , τ
2(n)
j )
,
where the superscript (n) indicates the parameter estimate from iteration n
of the EM algorithm. Substituting γij = E[Rij|Y ,Ψn] in place of Rij in
Equation (13) gives
Q(Ψ|Ψn) =E[log f(X|Ψ)|Y ,Ψn]
=
23040∑
i=1
3∑
j=1
γij log pij + γij log gj(yi, µj, τ
2
j ) (14)
In the maximisation step, we use a modification of the EM algorithm
known as the Expectation/Conditional Maximisation (CEM) (Meng and Ru-
bin, 1993). Here, the CEM replaces the M-step with a sequence of conditional
maximisation steps so that the function Q(Ψ|Ψn) is maximised for each pa-
rameter in turn, whilst keeping the remaining parameters fixed.
Maximisation of Q(Ψ|Ψn) with respect to pij, j = 1, 2, 3, with the con-
straint
∑3
j=1 pij = 1, gives the parameter estimates for pij at the (n + 1)
th
step as
pˆi
(n+1)
j =
∑23040
i=1 γij∑23040
i=1
∑3
j=1 γij
, j = 1, 2, 3.
Maximisation of Q(Ψ|Ψn) with respect to µj gives the parameter esti-
mates for µj at the (n+ 1)
th step as
µˆ
(n+1)
j =
∑23040
i=1 γijyi/(σ
2
i + τˆ
2(n)
j )∑23040
i=1 γij/(σ
2
i + τˆ
2(n)
j )
, j = 1, 2, 3.
Note the use of the estimates from the previous M-step for τ 2j , j = 1, 2, 3.
Numerical methods: We used numerical optimisation, in particular, the R (R
Development Core Team, 2011) function optimise (Brent, 2002) to find the
values of τ 2j that maximise
∑23040
i=1 γijgj(yi, µ
(n+1)
j , τ
2
j ) for j = 1, 2, 3. The R
function optimise uses a combination of golden section search and successive
parabolic interpolation to find the maximum over an interval. We considered
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the interval 0 ≤ τ 2j ≤ max(σ2i ), i = 1, . . . , 23040; j = 1, 2, 3. Note again the
use of the (n+ 1)th parameter estimate for µj.
Choosing initial parameter values: We modified a method proposed by Finch
et al. to obtain initial estimates of the hyperparameters given an initial
choice of the mixing proportions pij, j = 1, 2, 3 for the EM algorithm. For
each gene, there are two observations: the mean log ratio yi and the variance
σ2i . These pairs of observations were ordered according to the mean log
ratios yi. These values were then split into three samples consisting of the
smallest n1 observations, the smallest n2 of the remaining observations, and
the remaining observations, where n1 is the value 23040pi1 rounded to the
nearest integer and n2 is the value 23040pi2 rounded to the nearest integer.
For each of these three samples, the estimate of µj was initialised as the
sample mean of the observed mean log ratios. The initial value of τ 2j was
obtained by finding the value τ 2j that maximises
nj∑
i=1
log
 1√
2pi(τ 2j + σ
2
i )
exp
{
− (yi − µˆj)
2
2(τ 2j + σ
2
i )
} ,
where nj is the number of observations in the jth sample, yi and σ
2
i are the
pair of observations for each gene in the jth sample, and µˆj is the sample
mean of the yi in the jth sample. The R function optimise was used to find
this maximum over the range 0 ≤ τ 2j ≤ max(σ2i ), i = 1, . . . , nj, j = 1, 2, 3.
Karlis and Xekalaki (2003) compare via simulations a number of methods
for choosing initial values for the EM algorithm, including the one proposed
by Finch et al. (1989). They observed that for two-component and three-
component mixtures with equal mixing proportions for the initial values,
Finch et al.’s method generally locates the ‘global maximum’ more often
than other methods considered. They recommend that a mixed strategy is
used in the choice of initial values in the EM algorithm, as different initial
values may find a local but not a global maximum.
For each choice of initial parameter values, the EM algorithm is iterated
for a limited number of steps. The EM algorithm is then run with the initial
parameter values that give the largest likelihood for the initial iterations. In
this final iteration, the EM algorithm is iterated until a high level of accuracy
in the parameter estimates is achieved.
For the stem cell data, the initial values for the seven main mixing pro-
portions considered are set out in Table 3. These are: equally contributing
normals (Run 1); a single dominating normal (Runs 2, 3 and 4); and two
dominating normals (Runs 5, 6 and 7). For each choice of the initial parame-
ters, the EM algorithm was run for a limited number of steps, and the choice
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of initial parameters which produced the maximum log-likelihood was then
repeated for a larger number of iterations.
Run Initial pi1 Initial pi2 Initial pi3
1 0.33 0.33 0.33
2 0.8 0.1 0.1
3 0.1 0.8 0.1
4 0.1 0.1 0.8
5 0.1 0.45 0.45
6 0.45 0.1 0.45
7 0.45 0.45 0.1
Table 3: Initial mixing proportion for EM algorithm.
After each iteration of the EM algorithm, the absolute difference in each
of the parameter estimates compared to the previous iteration was calculated,
and the iterations continued until the maximum of these differences was less
than 10−5. The top five runs ordered by log-likelihood showed consistent
parameter estimates, and the initial values, pi1 = 0.45, pi2 = 0.1, pi3 = 0.1,
produced the maximum log-likelihood of 5368.77. These estimates were then
used for the initial values of the EM algorithm which was repeated until the
maximum difference in consecutive parameter estimates was less than 10−10.
The resulting final parameter estimates for the stem cell data are given
in Table 4.
Parameter Estimate
pi1 0.03177
pi2 0.3576
pi3 0.6107
µ1 -0.09135
µ2 -0.01845
µ3 0.008169
τ 21 0.3558
τ 22 0.01958
τ 23 5.426e-12
Table 4: Parameter estimates from the EM algorithm for stem cell data.
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Appendix 2: Monotonicity of posterior proba-
bilities of equivalence
Lemma 1: Suppose f(x) is a symmetric function with f(x) > 0 for all x
and consider numbers a, b, c, d, ` with −` < a < b < `, 0 < c, ` < d and
b− a = d− c. Then ∫ b
a
x2f(x)dx∫ b
a
f(x)dx
<
∫ d
c
x2f(x)dx∫ d
c
f(x)dx
Proof. By symmetry, we can assume b > 0 and |a| ≤ |b|. It is then sufficient
to consider the following three cases.
1. Case 1:b ≤ c: Observe that∫ b
a
x2f(x)dx∫ b
a
f(x)dx
< b2 and
∫ d
c
x2f(x)dx∫ d
c
f(x)dx
> c2
so the result follows.
2. Case 2:c < b and |a| ≤ c:
Let
m1 =
∫ c
a
x2f(x)dx∫ c
a
f(x)dx
, m2 =
∫ b
c
x2f(x)dx∫ b
c
f(x)dx
and m3 =
∫ d
b
x2f(x)dx∫ d
b
f(x)dx
and observe that m1 < c
2 < m2 < b
2 < m3. Since∫ b
a
x2f(x)dx∫ b
a
f(x)dx
is a weighted average of m1 and m2 and∫ d
c
x2f(x)dx∫ d
d
f(x)dx
is a weighted average of m2 and m3, the result follows.
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3. Case 3: c < b and |a| > c:
To have |a| > c requires a to be negative. Now let
m1 =
∫ −c
a
x2f(x)dx∫ −c
a
f(x)dx
, m0 =
∫ c
−c x
2f(x)dx∫ c
−c f(x)dx
, m2 =
∫ b
c
x2f(x)dx∫ b
c
f(x)dx
and m3 =
∫ d
b
x2f(x)dx∫ d
b
f(x)dx
,
and observe m0 < c
2 < m1 < m2 < b
2 < m3. Since∫ b
a
x2f(x)dx∫ b
a
f(x)dx
is a weighted average of m0, m1 and m2 and∫ d
c
x2f(x)dx∫ d
d
f(x)dx
is a weighted average of m2 and m3, the result follows.
Theorem 2: Suppose θ has prior distribution P (θ) and T |θ ∼ N(θ, σ2).
Consider numbers 0 < ` < ε and assume further that 0 < P (−ε < θ < ε) <
1. Then P (−ε < θ < ε | −` < T < `) is a decreasing function of σ2.
Proof. Observe that
P (−ε < θ < ε | −` < T < `) =
∫
|θ|≤ε P (θ)
∫ `
−` e
− 1
2σ2
(t−θ)2dtdθ∫∞
−∞ P (θ)
∫ `
−` e
− 1
2σ2
(t−θ)2dtdθ
=
∫
|θ|≤ε P (θ)
∫ `−θ
−`−θ e
− 1
2σ2
y2dydθ∫
θ≤ε P (θ)
∫ `−θ
−`−θ e
− 1
2σ2
y2dydθ +
∫
|θ|>ε P (θ)
∫ `−θ
−`−θ e
− 1
2σ2
y2dydθ
.
Taking ω = 1/(2σ2), it is sufficient to show that the posterior odds
r(ω) =
∫
|θ|≤ε P (θ)
∫ `−θ
−`−θ e
−ωy2dydθ∫
|θ|>ε P (θ)
∫ `−θ
−`−θ e
−ωy2dydθ
.
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is increasing in ω. Now observe
r′(ω) =
{(∫
|θ|≤ε
P (θ)
∫ `−θ
−`−θ
e−ωy
2
dydθ
)(∫
|θ|>ε
P (θ)
∫ `−θ
−`−θ
y2e−ωy
2
dydθ
)
−
(∫
|θ|≤ε
P (θ)
∫ `−θ
−`−θ
y2e−ωy
2
dydθ
)(∫
|θ|>ε
P (θ)
∫ `−θ
−`−θ
e−ωy
2
dydθ
)}
/{∫
|θ|>ε
P (θ)
∫ `−θ
−`−θ
e−ωy
2
dydθ
}2
.
Taking
A1 = inf|θ|>
∫ `−θ
−`−θ y
2e−ωy
2
dy∫ `−θ
−`−θ e
−ωy2dy
and A0 = sup
|θ|≤
∫ `−θ
−`−θ y
2e−ωy
2
dy∫ `−θ
−`−θ e
−ωy2dy
,
it follows that
r′(ω) ≥ (A1−A0)
(∫
|θ|≤ε P (θ)
∫ `−θ
−`−θ e
−ωy2dydθ
)(∫
|θ|>ε P (θ)
∫ `−θ
−`−θ e
−ωy2dydθ
)
{∫
|θ|>ε P (θ)
∫ `−θ
−`−θ e
−ωy2dydθ
}2
By Lemma 1, A1 > A0 so the proof is complete.
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